{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T13:54:49Z","timestamp":1770904489960,"version":"3.50.1"},"reference-count":101,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T00:00:00Z","timestamp":1744070400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Purpose<\/jats:title>\n                  <jats:p>An estimated 37 million people currently live with chronic kidney disease in the US, which places them at increased risk for kidney disease progression, cardiovascular disease, and mortality. This review discusses current standard-of-care management of patients with chronic kidney disease, identifies key gaps in care, and briefly highlights how pharmacists can address gaps in care as members of the multidisciplinary care team.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Summary<\/jats:title>\n                  <jats:p>Recent advances in guideline-directed medical therapies for patients with chronic kidney disease, including agents from the sodium-glucose cotransporter, glucagon-like peptide-1 receptor agonist, and nonsteroidal mineralocorticoid receptor antagonist classes, can dramatically improve cardiovascular-kidney-metabolic care and outcomes. Unfortunately, gaps in screening, diagnosis, and implementation of recommended therapies persist. Team-based models of care\u2014inclusive of the person with chronic kidney disease\u2014have the potential to significantly improve care and outcomes for people with chronic kidney disease by addressing current gaps in care.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>As members of the multidisciplinary care team, pharmacists can play a critical role in addressing current gaps in care, including optimized use of guideline-directed medical therapies, in patients with chronic kidney disease.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajhp\/zxaf045","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T16:40:29Z","timestamp":1744130429000},"page":"681-692","source":"Crossref","is-referenced-by-count":1,"title":["Using guideline-directed medical therapies to improve kidney and cardiovascular outcomes in patients with chronic kidney disease"],"prefix":"10.1093","volume":"82","author":[{"given":"Thelma","family":"Barber","sequence":"first","affiliation":[{"name":"National Kidney Foundation Voices for Kidney Health"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua J","family":"Neumiller","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapy, College of Pharmacy and Pharmaceutical Sciences, Washington State University , Spokane, WA"},{"name":"Providence Medical Research Center, Providence Inland Northwest Health , Spokane, WA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle A","family":"Fravel","sequence":"additional","affiliation":[{"name":"Division of Applied Clinical Sciences, College of Pharmacy, University of Iowa , Iowa City, IA,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"II","given":"Robert L","family":"Page","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado , Aurora, CO ,\u00a0","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine R","family":"Tuttle","sequence":"additional","affiliation":[{"name":"Providence Medical Research Center, Providence Inland Northwest Health , Spokane, WA"},{"name":"Nephrology Division, Department of Medicine, University of Washington School of Medicine , Seattle, WA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,4,8]]},"reference":[{"key":"2025061121163316200_CIT0001","author":"Centers for Disease Control and Prevention"},{"issue":"5","key":"2025061121163316200_CIT0002","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1053\/j.ajkd.2012.07.005","article-title":"KDOQI clinical practice guideline for diabetes and CKD: 2012 update","volume":"60","author":"National Kidney Foundation","year":"2012","journal-title":"Am J Kidney Dis"},{"issue":"9844","key":"2025061121163316200_CIT0003","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0140-6736(12)60572-8","article-title":"Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study","volume":"380","author":"Tonelli","year":"2012","journal-title":"Lancet"},{"issue":"9854","key":"2025061121163316200_CIT0004","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1016\/S0140-6736(12)61350-6","article-title":"Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis","volume":"380","author":"Fox","year":"2012","journal-title":"Lancet"},{"issue":"1","key":"2025061121163316200_CIT0005","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/s41413-023-00291-8","article-title":"Association of mineral and bone biomarkers with adverse cardiovascular outcomes and mortality in the German Chronic Kidney Disease (GCKD) cohort","volume":"11","author":"Reimer","year":"2023","journal-title":"Bone Res"},{"issue":"20","key":"2025061121163316200_CIT0006","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","article-title":"Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"issue":"20","key":"2025061121163316200_CIT0007","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1161\/CIR.0000000000001186","article-title":"A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"key":"2025061121163316200_CIT0008","author":"American Heart Association","journal-title":"The American Heart Association PREVENT Online Calculator"},{"issue":"6","key":"2025061121163316200_CIT0009","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1161\/CIRCULATIONAHA.123.067626","article-title":"Development and validation of the American Heart Association\u2019s PREVENT equations","volume":"149","author":"Khan","year":"2024","journal-title":"Circulation"},{"issue":"13","key":"2025061121163316200_CIT0010","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1056\/NEJMcp2000280","article-title":"Glucose-lowering drugs to reduce cardiovascular risk in type 2 diabetes","volume":"384","author":"Kalyani","year":"2021","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"2025061121163316200_CIT0011","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.2337\/dc24-SINT","article-title":"Standards of care in diabetes\u20132024","volume":"47","author":"American Diabetes Association Professional Practice Committee","year":"2024","journal-title":"Diabetes Care"},{"issue":"5","key":"2025061121163316200_CIT0012","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.kint.2022.08.012","article-title":"Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"102","author":"de Boer","year":"2022","journal-title":"Kidney Int"},{"issue":"5s","key":"2025061121163316200_CIT0013","first-page":"S1","article-title":"Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease","volume":"102","year":"2022","journal-title":"Kidney Int"},{"issue":"5","key":"2025061121163316200_CIT0014","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.eprac.2023.02.001","article-title":"American Association of Clinical Endocrinology consensus statement: comprehensive type 2 diabetes management algorithm\u20132023 update","volume":"29","author":"Samson","year":"2023","journal-title":"Endocr Pract"},{"issue":"4S","key":"2025061121163316200_CIT0015","first-page":"S117","article-title":"Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","year":"2024","journal-title":"Kidney Int"},{"issue":"19","key":"2025061121163316200_CIT0016","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1016\/j.jacc.2017.11.005","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"71","author":"Whelton","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"2025061121163316200_CIT0017","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1161\/HYPERTENSIONAHA.121.17323","article-title":"Albuminuria testing in hypertension and diabetes: an individual-participant data meta-analysis in a global consortium","volume":"78","author":"Shin","year":"2021","journal-title":"Hypertension"},{"issue":"9","key":"2025061121163316200_CIT0018","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.2337\/dc21-0723","article-title":"Chronic kidney disease testing among at-risk adults in the U.S. remains low: real-world evidence from a national laboratory database","volume":"44","author":"Alfego","year":"2021","journal-title":"Diabetes Care"},{"issue":"9","key":"2025061121163316200_CIT0019","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.2337\/dc20-2715","article-title":"Chronic kidney disease testing among primary care patients with type 2 diabetes across 24 U.S. health care organizations","volume":"44","author":"Stempniewicz","year":"2021","journal-title":"Diabetes Care"},{"issue":"7","key":"2025061121163316200_CIT0020","doi-asserted-by":"crossref","first-page":"e2326230","DOI":"10.1001\/jamanetworkopen.2023.26230","article-title":"Estimated prevalence and testing for albuminuria in US adults at risk for chronic kidney disease","volume":"6","author":"Chu","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"9","key":"2025061121163316200_CIT0021","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.2337\/dci23-0030","article-title":"Diabetic nephropathy: update on pillars of therapy slowing progression","volume":"46","author":"Naaman","year":"2023","journal-title":"Diabetes Care"},{"issue":"4","key":"2025061121163316200_CIT0022","doi-asserted-by":"crossref","first-page":"553","DOI":"10.2337\/cd22-0110","article-title":"Perspectives on chronic kidney disease with type 2 diabetes and risk management: practical viewpoints and a paradigm shift using a pillar approach","volume":"41","author":"Morales","year":"2023","journal-title":"Clin Diabetes"},{"issue":"12","key":"2025061121163316200_CIT0023","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"issue":"20","key":"2025061121163316200_CIT0024","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"issue":"12","key":"2025061121163316200_CIT0025","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"2025061121163316200_CIT0026","doi-asserted-by":"crossref","first-page":"111254","DOI":"10.1016\/j.mce.2021.111254","article-title":"Renin-angiotensin system and inflammation update","volume":"529","author":"Cantero-Navarro","year":"2021","journal-title":"Mol Cell Endocrinol"},{"issue":"12","key":"2025061121163316200_CIT0027","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.2215\/CJN.11491116","article-title":"Diabetic kidney disease: challenges, progress, and possibilities","volume":"12","author":"Alicic","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"2025061121163316200_CIT0028","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.kint.2022.05.012","article-title":"Molecular mechanisms and therapeutic targets for diabetic kidney disease","volume":"102","author":"Tuttle","year":"2022","journal-title":"Kidney Int"},{"issue":"2","key":"2025061121163316200_CIT0029","doi-asserted-by":"crossref","first-page":"248","DOI":"10.2337\/dbi18-0007","article-title":"Sodium-glucose cotransporter 2 inhibition and diabetic kidney disease","volume":"68","author":"Alicic","year":"2019","journal-title":"Diabetes"},{"issue":"15","key":"2025061121163316200_CIT0030","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.3390\/cells12151975","article-title":"Slowing the progression of diabetic kidney disease","volume":"12","author":"Blazek","year":"2023","journal-title":"Cells"},{"issue":"5","key":"2025061121163316200_CIT0031","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.kint.2018.04.025","article-title":"Sodium-glucose cotransporter 2 inhibition normalizes glucose metabolism and suppresses oxidative stress in the kidneys of diabetic mice","volume":"94","author":"Tanaka","year":"2018","journal-title":"Kidney Int"},{"issue":"3","key":"2025061121163316200_CIT0032","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1152\/physrev.00026.2020","article-title":"Regulation and metabolic functions of mTORC1 and mTORC2","volume":"101","author":"Szwed","year":"2021","journal-title":"Physiol Rev"},{"issue":"4","key":"2025061121163316200_CIT0033","doi-asserted-by":"crossref","first-page":"107954","DOI":"10.1016\/j.celrep.2020.107954","article-title":"Proximal tubule mTORC1 is a central player in the pathophysiology of diabetic nephropathy and its correction by SGLT2 inhibitors","volume":"32","author":"Kogot-Levin","year":"2020","journal-title":"Cell Rep"},{"issue":"3","key":"2025061121163316200_CIT0034","doi-asserted-by":"crossref","first-page":"818","DOI":"10.3390\/ijms19030818","article-title":"mTORC1 and nutrient homeostasis: the central role of the lysosome","volume":"19","author":"Rabanal-Ruiz","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"6","key":"2025061121163316200_CIT0035","doi-asserted-by":"crossref","first-page":"F1217","DOI":"10.1152\/ajprenal.00294.2016","article-title":"Solute transport and oxygen consumption along the nephrons: effects of Na+ transport inhibitors","volume":"311","author":"Layton","year":"2016","journal-title":"Am J Physiol Renal Physiol"},{"issue":"5","key":"2025061121163316200_CIT0036","doi-asserted-by":"crossref","first-page":"e167700","DOI":"10.1172\/JCI167700","article-title":"Digging deep into cells to find mechanisms of kidney protection by SGLT2 inhibitors","volume":"133","author":"Tuttle","year":"2023","journal-title":"J Clin Invest"},{"issue":"2","key":"2025061121163316200_CIT0037","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00125-016-4157-3","article-title":"Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition","volume":"60","author":"Vallon","year":"2017","journal-title":"Diabetologia"},{"issue":"1","key":"2025061121163316200_CIT0038","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1053\/j.ajkd.2020.08.003","article-title":"SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation","volume":"77","author":"Tuttle","year":"2021","journal-title":"Am J Kidney Dis"},{"issue":"22","key":"2025061121163316200_CIT0039","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"issue":"7","key":"2025061121163316200_CIT0040","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"2025061121163316200_CIT0041","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"issue":"24","key":"2025061121163316200_CIT0042","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"2025061121163316200_CIT0043","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"2025061121163316200_CIT0044","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"issue":"2","key":"2025061121163316200_CIT0045","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa2030186","article-title":"Sotagliflozin in patients with diabetes and chronic kidney disease","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"issue":"10365","key":"2025061121163316200_CIT0046","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials","volume":"400","author":"Nuffield Department of Population Health Renal Studies Group and SGLT2 Inhibitor Meta-analysis Cardio-Renal Trialists\u2019 Consortium","year":"2022","journal-title":"Lancet"},{"issue":"2","key":"2025061121163316200_CIT0047","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine","volume":"42","author":"Agarwal","year":"2021","journal-title":"Eur Heart J"},{"issue":"8","key":"2025061121163316200_CIT0048","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1001\/jamacardio.2023.1505","article-title":"Modifiability of composite cardiovascular risk associated with chronic kidney disease in type 2 diabetes with finerenone","volume":"8","author":"Agarwal","year":"2023","journal-title":"JAMA Cardiol"},{"issue":"10","key":"2025061121163316200_CIT0049","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1038\/ki.2011.48","article-title":"Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease","volume":"79","author":"Bertocchio","year":"2011","journal-title":"Kidney Int"},{"issue":"2","key":"2025061121163316200_CIT0050","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/s00125-023-06031-1","article-title":"Mineralocorticoid receptor overactivation: targeting systemic impact with non-steroidal mineralocorticoid receptor antagonists","volume":"67","author":"Savarese","year":"2024","journal-title":"Diabetologia"},{"issue":"1","key":"2025061121163316200_CIT0051","doi-asserted-by":"crossref","first-page":"sfad285","DOI":"10.1093\/ckj\/sfad285","article-title":"Optimization of guideline-directed medical therapies in patients with diabetes and chronic kidney disease","volume":"17","author":"Neumiller","year":"2024","journal-title":"Clin Kidney J"},{"issue":"3S","key":"2025061121163316200_CIT0052","first-page":"S1","article-title":"Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease","volume":"99","year":"2021","journal-title":"Kidney Int"},{"issue":"17","key":"2025061121163316200_CIT0053","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"2025061121163316200_CIT0054","first-page":"CD007004","article-title":"Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease","volume":"10","author":"Chung","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"23","key":"2025061121163316200_CIT0055","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"issue":"24","key":"2025061121163316200_CIT0056","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"2025061121163316200_CIT0057","volume-title":"Prescribing information","author":"Kerendia (finerenone) tablets","year":"2022"},{"key":"2025061121163316200_CIT0058","article-title":"A trial to learn how well finerenone works and how safe it is in adult participants with non-diabetic chronic kidney disease (FIND-CKD)","author":"Bayer","year":"2025"},{"key":"2025061121163316200_CIT0059","article-title":"A study to learn how well the treatment combination of finerenone and empagliflozin works and how safe it is compared to each treatment alone in adult participants with long-term kidney disease (chronic kidney disease) and type 2 diabetes (CONFIDENCE)","author":"Bayer","year":"2025"},{"issue":"2","key":"2025061121163316200_CIT0060","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/dom.14883","article-title":"Finerenone in patients across the spectrum of chronic kidney disease and type 2 diabetes by glucagon-like peptide-1 receptor agonist use","volume":"25","author":"Rossing","year":"2023","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"2025061121163316200_CIT0061","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.2337\/dc22-0294","article-title":"Finerenone in patients with chronic kidney disease and type 2 diabetes by sodium-glucose cotransporter 2 inhibitor treatment: the FIDELITY analysis","volume":"45","author":"Rossing","year":"2022","journal-title":"Diabetes Care"},{"issue":"1","key":"2025061121163316200_CIT0062","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ekir.2021.10.008","article-title":"Finerenone in predominantly advanced CKD and type 2 diabetes with or without sodium-glucose cotransporter-2 inhibitor therapy","volume":"7","author":"Rossing","year":"2022","journal-title":"Kidney Int Rep"},{"issue":"3","key":"2025061121163316200_CIT0063","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ekir.2021.12.013","article-title":"The kidney protective effects of the sodium-glucose cotransporter-2 inhibitor, dapagliflozin, are present in patients with CKD treated with mineralocorticoid receptor antagonists","volume":"7","author":"Provenzano","year":"2022","journal-title":"Kidney Int Rep"},{"key":"2025061121163316200_CIT0064","article-title":"Study to evaluate the efficacy (effect on disease) and safety of finerenone on morbidity (events indicating disease worsening) & mortality (death rate) in participants with heart failure and left ventricular ejection fraction (proportion of blood expelled per heart stroke) greater or equal to 40% (FINEARTS-HF)","author":"Bayer","year":"2024"},{"key":"2025061121163316200_CIT0065","article-title":"A study to determine the efficacy and safety of finerenone on morbidity and mortality among hospitalized heart failure patients (REDEFINE-HF)","author":"Colorado Prevention Center","year":"2024"},{"key":"2025061121163316200_CIT0066","article-title":"A study to evaluate finerenone on clinical efficacy and safety in patients with heart failure who are intolerant or not eligible for treatment with steroidal mineralocorticoid receptor antagonists (FINALITY-HF)","author":"Colorado Prevention Center","year":"2025"},{"issue":"4","key":"2025061121163316200_CIT0067","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/s41581-020-00367-2","article-title":"Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence","volume":"17","author":"Alicic","year":"2021","journal-title":"Nat Rev Nephrol"},{"issue":"1","key":"2025061121163316200_CIT0068","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1139\/bcb-2021-0365","article-title":"Cardiovascular protective effects of GLP-1: a focus on the MAPK signaling pathway","volume":"100","author":"Zhao","year":"2022","journal-title":"Biochem Cell Biol"},{"issue":"1","key":"2025061121163316200_CIT0069","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.cmet.2016.06.009","article-title":"The cardiovascular biology of glucagon-like peptide-1","volume":"24","author":"Drucker","year":"2016","journal-title":"Cell Metab"},{"issue":"10","key":"2025061121163316200_CIT0070","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.metabol.2012.03.002","article-title":"GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase a-mediated inhibition of renal NAD(P)H oxidases","volume":"61","author":"Hendarto","year":"2012","journal-title":"Metabolism"},{"issue":"5-6","key":"2025061121163316200_CIT0071","doi-asserted-by":"crossref","first-page":"419","DOI":"10.3109\/08977194.2015.1125349","article-title":"Exendin-4 attenuates renal tubular injury by decreasing oxidative stress and inflammation in streptozotocin-induced diabetic mice","volume":"33","author":"Sancar-Bas","year":"2015","journal-title":"Growth Factors"},{"issue":"4","key":"2025061121163316200_CIT0072","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s00125-010-2028-x","article-title":"Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes","volume":"54","author":"Kodera","year":"2011","journal-title":"Diabetologia"},{"issue":"4","key":"2025061121163316200_CIT0073","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1681\/ASN.2006070778","article-title":"Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db\/db mice","volume":"18","author":"Park","year":"2007","journal-title":"J Am Soc Nephrol"},{"issue":"12","key":"2025061121163316200_CIT0074","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1007\/s00125-021-05529-w","article-title":"The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials","volume":"64","author":"Lin","year":"2021","journal-title":"Diabetologia"},{"key":"2025061121163316200_CIT0075","doi-asserted-by":"crossref","first-page":"100502","DOI":"10.1016\/j.ajpc.2023.100502","article-title":"Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: a review of their kidney and heart protection","volume":"14","author":"Michos","year":"2023","journal-title":"Am J Prev Cardiol"},{"issue":"9","key":"2025061121163316200_CIT0076","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1056\/NEJMoa1616011","article-title":"Liraglutide and renal outcomes in type 2 diabetes","volume":"377","author":"Mann","year":"2017","journal-title":"N Engl J Med"},{"issue":"19","key":"2025061121163316200_CIT0077","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"10193","key":"2025061121163316200_CIT0078","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"issue":"8","key":"2025061121163316200_CIT0079","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S2213-8587(18)30104-9","article-title":"Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial","volume":"6","author":"Tuttle","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"2025061121163316200_CIT0080","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.kint.2022.12.028","article-title":"Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placebo","volume":"103","author":"Tuttle","year":"2023","journal-title":"Kidney Int"},{"issue":"8","key":"2025061121163316200_CIT0081","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1161\/CIRCULATIONAHA.121.055459","article-title":"Effect of the glucagon-like peptide-1 receptor agonists semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes: pooled analysis of SUSTAIN 6 and LEADER","volume":"145","author":"Shaman","year":"2022","journal-title":"Circulation"},{"issue":"9","key":"2025061121163316200_CIT0082","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1093\/ndt\/gfad009","article-title":"The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease","volume":"38","author":"Rossing","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"2025061121163316200_CIT0083","article-title":"A research study to see how semaglutide works compared to placebo in people with type 2 diabetes and chronic kidney disease (FLOW)","author":"Novo Nordisk A\/S","year":"2024"},{"issue":"2","key":"2025061121163316200_CIT0084","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"issue":"11","key":"2025061121163316200_CIT0085","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S2213-8587(22)00243-1","article-title":"Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial","volume":"10","author":"Heerspink","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025061121163316200_CIT0086","article-title":"A study of tirzepatide (LY3298176) in participants with overweight or obesity and chronic kidney disease with or without type 2 diabetes (TREASURE-CKD)","author":"Eli Lilly and Company","year":"2025"},{"issue":"10","key":"2025061121163316200_CIT0087","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.2337\/dc21-0529","article-title":"Prescribing trends of antidiabetes medications in patients with type 2 diabetes and diabetic kidney disease, a cohort study","volume":"44","author":"Harris","year":"2021","journal-title":"Diabetes Care"},{"issue":"7","key":"2025061121163316200_CIT0088","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1111\/jch.13563","article-title":"Prescription of renin-angiotensin-aldosterone system inhibitors (RAASi) and its determinants in patients with advanced CKD under nephrologist care","volume":"21","author":"Pecoits-Filho","year":"2019","journal-title":"J Clin Hypertens"},{"issue":"6","key":"2025061121163316200_CIT0089","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1097\/MAJ.0000000000000475","article-title":"Underprescription of renin-angiotensin system blockers in moderate to severe chronic kidney disease","volume":"349","author":"Shirazian","year":"2015","journal-title":"Am J Med Sci"},{"issue":"12","key":"2025061121163316200_CIT0090","doi-asserted-by":"crossref","first-page":"e1918169","DOI":"10.1001\/jamanetworkopen.2019.18169","article-title":"Clinical characteristics of and risk factors for chronic kidney disease among adults and children: an analysis of the CURE-CKD Registry","volume":"2","author":"Tuttle","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"1","key":"2025061121163316200_CIT0091","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1186\/s12882-019-1558-9","article-title":"Rationale and design of a multicenter chronic kidney disease (CKD) and at-risk for CKD electronic health records-based registry: CURE-CKD","volume":"20","author":"Norris","year":"2019","journal-title":"BMC Nephrol"},{"issue":"10","key":"2025061121163316200_CIT0092","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1111\/dom.15194","article-title":"Prescription of guideline-directed medical therapies in patients with diabetes and chronic kidney disease from the CURE-CKD Registry, 2019-2020","volume":"25","author":"Nicholas","year":"2023","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"2025061121163316200_CIT0093","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.cardfail.2022.09.013","article-title":"Managing heart failure in patients on dialysis: state-of-the-art review","volume":"29","author":"Khan","year":"2023","journal-title":"J Card Fail"},{"issue":"5","key":"2025061121163316200_CIT0094","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jchf.2019.02.009","article-title":"Medical management of heart failure with reduced ejection fraction in patients with advanced renal disease","volume":"7","author":"Hein","year":"2019","journal-title":"JACC Heart Fail"},{"issue":"9","key":"2025061121163316200_CIT0095","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1161\/CIRCULATIONAHA.121.052792","article-title":"Evidence-based medical therapy in patients with heart failure with reduced ejection fraction and chronic kidney disease","volume":"145","author":"Beldhuis","year":"2022","journal-title":"Circulation"},{"issue":"3","key":"2025061121163316200_CIT0096","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1093\/ndt\/gfac283","article-title":"Overcoming barriers to implementing new guideline-directed therapies for chronic kidney disease","volume":"38","author":"Nee","year":"2023","journal-title":"Nephrol Dial Transplant"},{"issue":"19","key":"2025061121163316200_CIT0097","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/j.jacc.2015.09.025","article-title":"The role of the clinical pharmacist in the care of patients with cardiovascular disease","volume":"66","author":"Dunn","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"2025061121163316200_CIT0098","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.cardfail.2023.02.011","article-title":"Multidisciplinary care in heart failure services","volume":"29","author":"Sokos","year":"2023","journal-title":"J Card Fail"},{"issue":"1","key":"2025061121163316200_CIT0099","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s12882-023-03210-5","article-title":"Impact of a multidisciplinary approach involving clinical pharmacist on resolving drug related problems in chronic kidney patients: a prospective interventional study","volume":"24","author":"Pehlivanli","year":"2023","journal-title":"BMC Nephrol"},{"issue":"6","key":"2025061121163316200_CIT0100","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1097\/MNH.0b013e328365b364","article-title":"New models of chronic kidney disease care including pharmacists: improving medication reconciliation and medication management","volume":"22","author":"St Peter","year":"2013","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"3","key":"2025061121163316200_CIT0101","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1177\/0897190019876499","article-title":"A pilot study embedding clinical pharmacists within an interprofessional nephrology clinic for the initiation and monitoring of empagliflozin in diabetic kidney disease","volume":"34","author":"Triantafylidis","year":"2021","journal-title":"J Pharm Pract"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxaf045\/62888032\/zxaf045.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/82\/12\/681\/62888032\/zxaf045.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/82\/12\/681\/62888032\/zxaf045.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T01:16:50Z","timestamp":1749691010000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/82\/12\/681\/8108093"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,8]]},"references-count":101,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,4,8]]},"published-print":{"date-parts":[[2025,6,11]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxaf045","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6,15]]},"published":{"date-parts":[[2025,4,8]]}}}